Discovery of a novel NAMPT inhibitor that selectively targets NAPRT-deficient EMT-subtype cancer cells and alleviates chemotherapy-induced peripheral neuropathy
Min‐Jee Kim, Hyeyoung Kim, Bu-Gyeong Kang, Joo‐Young Lee, Taegun Kim, Hwanho Lee, Jane Jung, Myung Joon Oh, Seungyoon Seo, Myung‐Jeom Ryu, Yeojin Sung, Yunji Lee, Jeonghun Yeom, Gyoonhee Han, Sun‐Shin Cha, Hosung Jung, Hyun Seok Kim
Abstract
This study demonstrates that A4276 selectively targets NAPRT-deficient EMT-subtype cancer cells and prevents chemotherapy-induced peripheral neuropathy, highlighting its potential as a promising anti-cancer agent for use in cancer monotherapy or combination therapy with conventional chemotherapeutics.
Topics & Concepts
Nicotinamide phosphoribosyltransferaseNAD+ kinaseCancer researchCancerCancer cellIn vivoCytotoxicityMedicinePharmacologyIn vitroChemistryEnzymeBiologyBiochemistryInternal medicineBiotechnologySirtuins and Resveratrol in MedicinePARP inhibition in cancer therapyToxin Mechanisms and Immunotoxins